Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 11
2019 11
2020 10
2021 18
2022 11
2023 10
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study.
Nagahara A, Uemura M, Sato M, Nakata W, Tsujihata M, Takao T, Matsumura S, Nishimura K, Takada S, Iwanishi T, Kobayashi Y, Ishizuya Y, Takada T, Okada K, Inoue H, Kato T, Hatano K, Kawashima A, Ujike T, Fujita K, Nonomura N. Nagahara A, et al. Jpn J Clin Oncol. 2024 Feb 1:hyae004. doi: 10.1093/jjco/hyae004. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 38305451
Safety and efficacy of an α1 -blocker plus mirabegron compared with an α1 -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta-analysis.
Herschorn S, Tarcan T, Jiang YH, Chung E, Abdul Hadi F, Steup A, Sumarsono B. Herschorn S, et al. Neurourol Urodyn. 2024 Mar;43(3):604-619. doi: 10.1002/nau.25399. Epub 2024 Jan 30. Neurourol Urodyn. 2024. PMID: 38291827 Review.
Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study.
Nakamura Y, Horie I, Kitamura T, Kusunoki Y, Nishida K, Yamamoto A, Hirota Y, Fukui T, Maeda Y, Minami M, Matsui T, Kawakami A, Abiru N. Nakamura Y, et al. Diabetes Obes Metab. 2024 May;26(5):1605-1614. doi: 10.1111/dom.15458. Epub 2024 Jan 22. Diabetes Obes Metab. 2024. PMID: 38253809
Sodium-glucose co-transporter 2 inhibitor therapy reduces the administration frequency of anti-vascular endothelial growth factor agents in patients with diabetic macular oedema with a history of anti-vascular endothelial growth factor agent use: A cohort study using the Japanese health insurance claims database.
Ishibashi R, Inaba Y, Koshizaka M, Takatsuna Y, Tatsumi T, Shiko Y, Kashiwagi Y, Maezawa Y, Kawasaki Y, Kawakami E, Yamamoto S, Yokote K. Ishibashi R, et al. Diabetes Obes Metab. 2024 Apr;26(4):1510-1518. doi: 10.1111/dom.15454. Epub 2024 Jan 19. Diabetes Obes Metab. 2024. PMID: 38240052
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis.
Kashiwagi A, Shoji S, Kosakai Y, Yoshinaga Y, Rokuda M. Kashiwagi A, et al. J Diabetes Investig. 2024 Mar;15(3):374-387. doi: 10.1111/jdi.14123. Epub 2023 Dec 19. J Diabetes Investig. 2024. PMID: 38112598 Free PMC article.
64 results